Chapter 2 - My Father Had Put One Clause Into the Company Nobody Respected
Halcyon Biotech began in my parents’ garage.
Not metaphorically.
Literally.
My father built the first clean bench from stainless-steel restaurant equipment he bought at auction.
My mother kept spreadsheets at the kitchen table.
I was twenty-seven.
Cassandra was twenty-eight.
Julian was thirty-one.
We had no money.
No major investors.
No industry connections.
Just data.
A prototype.
And a belief that damaged neural tissue could be coaxed into repairing itself through targeted cellular signaling.
My father funded the first eighteen months.
Not because he was rich.
Because he believed me.
When institutional investors finally appeared, he agreed to convert much of his early funding into founder shares.
But he insisted on one thing.
The core invention would remain separate.
“Companies fail,” he told me.
“Boards change.”
“Investors get scared.”
“Your work needs somewhere to live if everything around it goes bad.”
Our lawyer created Hart Research Trust.
The trust owned the original molecular platform.
Halcyon received an exclusive license to develop and commercialize it.
Not ownership.
Everyone understood that at the beginning.
Then years passed.
New patents were filed.
New employees arrived.
The company grew.
Julian became CFO.
Cassandra became Chief Strategy Officer.
Investors began talking about Halcyon as if the company owned everything.
I corrected them at first.
Then stopped.
The distinction felt technical.
It wasn’t.
Six years earlier, Julian signed a revised licensing agreement extending Halcyon’s rights.
Buried inside was a clause triggered by founder misconduct.
If Halcyon executives attempted unauthorized transfer of core intellectual property, the trust could terminate the license immediately.
My father had insisted on it.
Julian called it paranoid.
Then signed anyway.
At the ballroom, the first person to understand what had happened was our outside patent counsel.
I heard him say:
“If Hart Research terminated the license before those assignments, then the assignments are void.”
Cassandra snapped:
“No. Elena transferred the patents.”
“I transferred development patents,” I said. “Not the underlying platform.”
Julian approached me.
“You planned this?”
“No.”
“When?”
“After the explosion.”
He grabbed my elbow.
Not violently.
Desperately.
“Elena, listen to me.”
I pulled away.
“No.”
Cassandra shouted toward the stage crew:
“Turn off the display!”
Nothing happened.
The system continued showing the documents.
Because the remote didn’t control the projector.
It controlled access to an encrypted evidence package already mirrored to every authorized attendee portal in the ballroom.
Phones began buzzing.
Dozens.
Then hundreds.
Journalists were receiving it.
Investors.
Lawyers.
Board members.
Cassandra realized.
“You sent this outside?”
“Yes.”
“To who?”
“Anyone who was invited to invest tonight.”
Someone laughed nervously.
Not because it was funny.
Because five hundred million dollars of promised financing had just become legally radioactive.
Then one of the pharmaceutical representatives spoke.
“What exactly did Orchid buy for two billion?”
Good question.
I turned toward his voice.
“The next generation.”
Cassandra stopped moving.
Aurum 1.0 was impressive.
The technology she stole.
What I sold was Aurum 2.
The version I finished two weeks before the explosion.
Different delivery system.
Different molecular architecture.
Far stronger efficacy in preclinical models.
And completely outside Halcyon’s license because the new architecture had been developed under a separate research vehicle.
Julian whispered:
“You told me version two failed.”
“Yes.”
“Why?”
I smiled.
“Because someone inside my own house was reading my lab reports before I came home.”
Silence.
Then Julian said:
“What are you talking about?”
I faced him.
May you like
“I’m talking about the reports Cassandra was receiving from your private email account.”
And for the first time that night, my husband sounded afraid for reasons that had nothing to do with money.
